Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 15, 2025 07:45 ET | Source: Upstream Bio

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

Translational Data Presented at EACCI Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor
June 05, 2025 07:00 ET | Source: Upstream Bio

Upstream Bio to Present Mechanistic Insights into Verekitug’s Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025

Upstream Bio to Present Mechanistic Insights into Verekitug’s Enhanced Potency via TSLP Receptor Targeting at EACCI 2025
May 20, 2025 07:00 ET | Source: Upstream Bio

Upstream Bio Appoints Stacy Price as Chief Technology Officer

Upstream Bio Appoints Stacy Price as Chief Technology Officer
May 06, 2025 07:00 ET | Source: Upstream Bio

Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs

Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs
November 21, 2024 08:00 ET | Source: Upstream Bio

Upstream Bio to Participate in the Piper Sandler 36th Annual Healthcare Conference

Upstream Bio CEO to participate in fireside chat at Piper Sandler
May 15, 2024 07:00 ET | Source: Upstream Bio, Inc.

Upstream Bio to Present Results from a Dose Ranging Study of Verekitug (UPB-101) in Adults with Asthma at the American Thoracic Society (ATS) International Conference

Upstream Bio will present clinical data from dose-ranging study of verekitug (UPB-101) in adults with asthma at the American Thoracic Society conference